Akums Drugs and Pharmaceuticals544222Investor deck

Final monitoring agency report: IPO proceeds of Rs 6,800.00 million fully utilised, no deviation

CRISIL Ratings' final monitoring report confirms the IPO money of Rs 6,800.00 million is fully utilised as of Sept 30, 2026.

By ScoutQuest · Tue 3 Nov 2026, 2:26 PM IST · 1 min read

Rs 6,800.00 millionGross IPO proceeds

Revised net proceeds₹6,421.80 Mn

Revised issue expensesRs 378.21 million

Gross IPO proceeds Rs 6,800.00 million: Revised net proceeds ₹6,421.80 Mn, Revised issue expenses Rs 378.21 million.

IPO Proceeds Fully Utilised: Rs 6,800.00 million as of Sept 30, 2026
Debt Repayment - Company: Rs 1,599.10 million
Debt Repayment - Subsidiaries: Rs 2,270.90 million
Working Capital Deployment: Rs 550.00 million
Acquisitions: Rs 301.80 million

What this update is

A monitoring agency checks that a company spends IPO money only on the purposes promised in its offer document. CRISIL Ratings has issued its final such report for the quarter ended September 30, 2026.

Key outcome

Entire IPO proceeds of Rs 6,800.00 million fully utilised as on September 30, 2026.
Deviation from objects: Not applicable.
No utilisation during this quarter; all objects were already fully spent earlier.
No favourable or unfavourable events affecting the objects were reported.

How the net proceeds of Rs 6,421.80 million were used

Repayment of company's debt: Rs 1,599.10 million (fully used in Sep-24 quarter)
Repayment of subsidiaries' debt (Maxcure Nutravedics and Pure and Cure Healthcare): Rs 2,270.90 million (Dec-24 quarter)
Working capital: Rs 550.00 million (Mar-25 quarter)
Acquisitions: Rs 301.80 million (Jun-26 quarter)
General corporate purposes: Rs 1,700.00 million (Jun-26 quarter)

Issue expenses and reallocation

Issue expenses were estimated at Rs 426.30 million but came in at Rs 378.21 million. The saving of Rs 48.10 million was reallocated in the March 2026 quarter: Rs 25.00 million to general corporate purposes and Rs 23.10 million to acquisitions, approved by the Board on February 13, 2026.

Small pending item

Rs 0.98 million of issue expenses paid in August 2026 was reimbursed from the monitoring account on October 5, 2026, due to administrative delay. After that, the account balance is nil.

What it means

The IPO money has been spent as promised, largely on cutting debt. Quarterly monitoring reports will no longer be shared.

Also from Akums Drugs and Pharmaceuticals